QLS5132 Goes after CLDN6 in Ovarian Cancer

ABSTRACT: For patients with advanced platinum-resistant ovarian cancer, treatment options remain limited, but new agents are emerging. One is QLS5132, an antibody-drug conjugate targeting CLDN6; early data from a phase I trial indicates that it has a favorable safety profile and appears active in this disease.

Publication Details

Journal
Cancer Discovery
Published
2026-04-21
DOI
https://doi.org/10.1158/2159-8290.cd-nw2026-0044
Primary Topic
HER2/EGFR in Cancer Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

QLS5132 Goes after CLDN6 in Ovarian Cancer

Cancer Discovery
HER2/EGFR in Cancer Research
article

QLS5132 Goes after CLDN6 in Ovarian Cancer

article en

Abstract

ABSTRACT: For patients with advanced platinum-resistant ovarian cancer, treatment options remain limited, but new agents are emerging. One is QLS5132, an antibody-drug conjugate targeting CLDN6; early data from a phase I trial indicates that it has a favorable safety profile and appears active in this disease.

Cancer Discovery
Good health and well-being
Openalex Percentile: Top 9%
HER2/EGFR in Cancer Research
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

QLS5132 Goes after CLDN6 in Ovarian Cancer · Cancer Discovery (2026) | TGRS Research Map | TGRS